Elicio Therapeutics
ELTX
20 hedge funds and large institutions have $2.68M invested in Elicio Therapeutics in 2024 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 8 increasing their positions, 1 reducing their positions, and 3 closing their positions.
700% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 1
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
11% more funds holding
Funds holding: 18 → 20 (+2)
1.48% more ownership
Funds ownership: 4.83% → 6.32% (+1.5%)
13% less capital invested
Capital invested by funds: $3.08M → $2.68M (-$400K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$846K |
| 2 |
AI
Arena Investors
Purchase,
New York
|
+$423K |
| 3 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$412K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$201K |
| 5 |
BlackRock
New York
|
+$153K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CM
CM Management
Gulf Breeze,
Florida
|
-$211K |
| 2 |
Renaissance Technologies
New York
|
-$89K |
| 3 |
NCM
Northwest Capital Management
Lake Oswego,
Oregon
|
-$2.66K |
| 4 |
Wells Fargo
San Francisco,
California
|
-$380 |
ELTX Hedge Fund Activity: Q2 2024 in Review
20 of the 6,938 institutional investors tracked by Wall St. Rank reported a position in Elicio Therapeutics (ELTX) for Q2 2024, worth a combined $2.68M — down 13% from $3.08M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new ELTX positions and 3 closed out — a net gain of 2 holders — while 8 added to existing stakes and 1 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $846K. The largest seller was CM Management, cutting an estimated $211K.
- 20 institutional investors held Elicio Therapeutics (ELTX) as of Q2 2024, up from 18 in Q1 2024.
- Funds reported $2.68M of Elicio Therapeutics stock for Q2 2024, down 13% quarter-over-quarter.
- 5 funds opened new Elicio Therapeutics positions in Q2 2024 and 3 closed out, a net change of +2 holders.
- The largest Elicio Therapeutics buyer in Q2 2024 was Armistice Capital, an estimated $846K added.
- The largest Elicio Therapeutics seller in Q2 2024 was CM Management, an estimated $211K sold.
Based on aggregated 13F filings for Q2 2024.